Hansoh Pharmaceutical Group
Hansoh Pharmaceutical Group Company Limited is a research-driven biopharmaceutical company in China engaged in the development, manufacturing, and commercialization of innovative small-molecule therapies and biologics. The company focuses on major therapeutic areas, including oncology, central nervous system disorders, metabolic diseases, autoimmune conditions, and anti-infectives. Primary revenue drivers include the commercial sales of proprietary innovative prescription drugs and high-value generic formulations across domestic clinical markets. Hansoh Pharmaceutical serves hospitals, medical centers, specialty clinics, and retail pharmacy networks throughout mainland China. The enterprise holds a top-tier position among domestic Chinese biopharmaceutical innovators, supported by extensive research and clinical trial capabilities. Hansoh Pharmaceutical Group Company Limited is headquartered in Lianyungang, China, and its common shares are listed on the Stock Exchange of Hong Kong.
22 of the funds FundTelligence covers report a position in Hansoh Pharmaceutical Group.
- Legal name
- Hansoh Pharmaceutical Group Co Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 22
Funds holding Hansoh Pharmaceutical Group
- DWS Invest Chinese Equities — DWS · 1.38 % (full portfolio disclosed, June 2026)
- Templeton China Fund — Franklin Templeton · 1.27 % (full portfolio disclosed, September 2026)
- Templeton Asian Growth Fund — Franklin Templeton · 1.1 % (full portfolio disclosed, September 2026)
- Handelsbanken Helse Tema — Handelsbanken · 0.38 % (full portfolio disclosed, October 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.33 % (full portfolio disclosed, September 2026)
- Danske Invest Global Emerging Markets Index Restricted — Danske Invest · 0.09 % (full portfolio disclosed, July 2026)
- Storebrand Emerging Markets — Storebrand · 0.08 % (full portfolio disclosed, October 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.07 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 22 funds holding it.